MARKET

ANIP

ANIP

ANI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.95
+0.15
+0.47%
After Hours: 31.95 0 0.00% 16:00 09/24 EDT
OPEN
31.36
PREV CLOSE
31.80
HIGH
32.17
LOW
30.71
VOLUME
87.98K
TURNOVER
--
52 WEEK HIGH
40.00
52 WEEK LOW
23.55
MARKET CAP
407.76M
P/E (TTM)
-22.3771
1D
5D
1M
3M
1Y
5Y
ANI Pharmaceuticals To Present At Cantor Virtual Global Healthcare Conference 2021 Sept. 30 At 8:00 a.m. ET
`
Benzinga · 6d ago
BRIEF-Ani Pharmaceuticals Announces Launch Of Nebivolol Tablets
reuters.com · 09/17 10:55
ANI Pharma Reports Launch Of Nebivolol Tablets
-- Current annual market for reference listed drug (“RLD”) Bystolic® totals more than $1 billion -- -- Simultaneous launch from two manufacturing sites -- BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI
Current annual market for reference listed drug (“RLD”) Bystolic® totals more than $1 billion -- -- Simultaneous launch from two manufacturing sites -- BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI · 09/17 10:51
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
-- Simultaneous launch from two manufacturing sites --
Business Wire · 09/17 10:50
Looking Into ANI Pharmaceuticals's Return On Capital Employed
Benzinga Pro data, ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 sales of $48.62 million. Earnings fell to a loss of $15.55 million, resulting in a 610.77% decrease from last quarter.
Benzinga · 09/09 17:15
Is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Shareholder Ownership Skewed Towards Insiders?
If you want to know who really controls ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ), then you'll have to look at the...
Simply Wall St. · 09/03 11:12
ANI Pharma's Purified Cortrophin Gel Application Under FDA Review
Benzinga · 08/31 13:58
BRIEF-Ani Pharmaceuticals Announces FDA Acceptance Of Purified Cortrophin® Gel Supplemental New Drug Application For Multiple Indications
reuters.com · 08/31 11:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIP. Analyze the recent business situations of ANI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIP stock price target is 45.00 with a high estimate of 60.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 238
Institutional Holdings: 8.73M
% Owned: 68.38%
Shares Outstanding: 12.76M
TypeInstitutionsShares
Increased
37
288.80K
New
18
129.27K
Decreased
39
448.83K
Sold Out
8
49.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Patrick Walsh
President/Chief Executive Officer/Director
Nikhil Lalwani
Chief Financial Officer/Senior Vice President - Finance/Secretary
Stephen Carey
Senior Vice President
Ori Gutwerg
Senior Vice President
James Marken
General Manager
Davinder Singh
Other
Christopher Mutz
Independent Director
Robert Brown
Independent Director
Thomas Haughey
Independent Director
David Nash
Independent Director
Antonio Pera
Independent Director
Jeanne Thoma
No Data
  • All
  • Financials
  • Insiders
More
About ANIP
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Webull offers kinds of ANI Pharmaceuticals Inc stock information, including NASDAQ:ANIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIP stock methods without spending real money on the virtual paper trading platform.